MedTrace Logo

Safety and Efficacy of AGN201781 in Neuropathic Pain

NCT00533351 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2016-02-24

Study results available
· View outcomes & findings →

Summary

This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia

Conditions

  • Neuralgia

Interventions

DRUG

AGN201781

AGN201781 50 mg capsules three-times daily for 2 weeks

DRUG

placebo

placebo 50 mg capsules three-times daily for 2 weeks

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Australia
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533351 on ClinicalTrials.gov